Digital Health App Tracks Pain Progress With Neurostimulation Therapy
Patients will be able to share information collected in the app with health care providers to provide a comprehensive assessment of the SCS or DRG therapy.
Musculoskeletal Disorders
Locally-Delivered Sitaxsentan Designated Orphan Drug for Systemic Sclerosis
TMB-003 is a locally delivered formulation of sitaxsentan, a highly selective endothelin receptor antagonist.
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Kineret Approved for Deficiency of IL-1 Receptor Antagonist
Kineret blocks the biologic activity of IL-1 alpha and beta by competitively inhibiting IL-1 binding to the IL-1 type I receptor.
MPR Weekly Dose Podcast Episode 62
Its been a long year, but the monumental efforts to achieve a COVID-19 vaccine are bearing some fruits, we about that, and also a fully at home diagnostic COVID test, as well as new findings related to glucosamine supplements and a novel treatment for eosinophilic esophagitis. And as ever, one final movie trivia ‘guess the quote’ to end the year!
Continuing Treatment Not Beneficial After 5 Years of Bisphosphonates
No difference seen in cumulative incidence of hip fracture for continuing therapy for two, five additional years versus discontinuing
Antifibrotic Therapy Gets Orphan Drug Status for Systemic Sclerosis
ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands.
FDA to Review AVT02, a High Concentration Biosimilar to Adalimumab
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
RediTrex Now Available for RA, pJIA, Psoriasis Treatment
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
Study Supports Switching Between Upadacitinib and Adalimumab in RA
Researchers evaluated the safety and efficacy of switching between upadacitinib and adalimumab in patients with rheumatoid arthritis with nonresponse or incomplete response to initial therapy.
